Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

  • ID: 4377330
  • Report
  • Region: Global
  • 39 Pages
  • La Merie Publishing
1 of 3

This Competitive Intelligence report about Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017 provides a competitor evaluation in the field of antibodies, vaccines and engineered chimeric antigen receptor (CAR) T-cells targeting mesothelin as of August 2017.

Mesothelin is a surface marker protein overexpressed in many cancers and is a suitable target for directing immunotherapeutics to mesothelin expressing tumors, such as malignant pleural mesothelioma, mesothelioma and pancreatic, non-small cell lung, ovarian, endometrial and gastric cancers.

The report includes a compilation of currently active projects in research and development of antibodies, vaccines and engineered T-cells directed against mesothelin. In addition, the report lists company- and institution-specific R&D pipelines of anti-Mesothelin Immunotherapeutics.

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Note: Product cover images may vary from those shown
2 of 3

1. Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

  • Mesothelin-Targeted Antibodies
  • Mesothelin-Targeted Vaccines
  • Mesothelin-Targeted Engineered CAR T-Cells

2. Corporate & Institutional Anti-Mesothelin R&D Pipelines

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll